The two companies have initiated a scientific collaboration with the aim to boost cancer treatment technology.
It is a preclinical research collaboration and the two collaborators will be exploring synergies between their two technologies to further enhance the effect of treatments of cancer and infectious diseases. They will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
“I’m very pleased to announce another research agreement with a key player within the field of immunotherapies, which is the second collaboration initiated this year. We believe that the PCI technology has the potential to play a role in the realization of several new therapeutic treatments, and we look forward to exploring synergies with Bavarian Nordic’s unique and innovative technologies,” says Per Walday, CEO of PCI Biotech.
Photo of Paul Chaplin, CEO of Bavarian Nordic and Per Walday, CEO of PCI Biotech